LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver ...

This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after ...

Fatty liver disease is becoming increasingly common, yet many people still underestimate how serious it can be. Because the condition often develops quietly and without noticeable symptoms in its ...

Citius Oncology, Inc. ("Citius Oncology") , an oncology?focused biopharmaceutical company and majority?owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , today announced positive ...

Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response ...

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

Fatty liver disease is becoming increasingly common, yet many people still misunderstand what causes it and who is at risk.

PYRUKYND is also approved for adults with PK deficiency in the U.S. and Europe, and a marketing application for PYRUKYND in thalassemia is currently under review by the European Commission. In the U.S ...

Dermatomyositis is a rare autoimmune disease that typically affects the skin, muscle and respiratory system. Patients with ...

Fatty liver disease sounds mild, almost harmless. That name alone pushes many people into denial. There is usually no pain, ...

Beam Therapeutics Inc. buy thesis: base-editing gene therapy leaders, risto-cel & BEAM-302 catalysts, strong cash runway.